Tekla Funds Approve New Investment Advisory Agreements With abrdn Inc.
Tekla Capital Management LLC (Tekla) announced today that the requisite vote has been attained to approve the new investment advisory agreement with abrdn Inc. for each of its four closed-end funds (the Funds).
Tekla Funds Implore Shareholders of THQ and THW to Vote Immediately to Realize Potential Cost Savings for the Funds
Tekla Healthcare Investors (HQH) today announced at the Special Meetings of shareholders (“Special Meetings”) that the requisite vote had been attained for the proposal to approve the new investment advisory agreement with abrdn Inc.
Tekla Funds Urge Shareholders to Vote Immediately to Guarantee Reduced Fund Expenses
Tekla Life Sciences Investors (HQL) announced at the Joint Special Meetings of shareholders (“Special Meetings”) that the requisite vote had been reached to approve the new investment advisory agreement with abrdn Inc.
Tekla Funds Announce Adjournment of Special Meetings and Implore Shareholders to Vote Their Shares Immediately
Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW), (the “Funds”) today announced that their joint first special meetings of shareholders (“Special Meetings”) were adjourned again until October 3, 2023 at 9:00 a.m. EDT.
Tekla Funds Announce Second Adjournment of Special Meetings and Urge Shareholder Participation to Limit the Need for Further Solicitation Efforts
Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW), (the “Funds”) today announced that their joint first special meetings of shareholders (“Special Meetings”) were adjourned for a second time until September 12, 2023 at 9:00 a.m. EDT due to lack of a quorum on the proposal to approve a new investment advisory agreement with abrdn, Inc. Shareholders as of the June 16, 2023 record date who have not yet voted on the Proposal are urged to do so promptly per the instructions below.
Tekla Funds Announce Adjournment of Special Meetings
Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW), (the “Funds”) today announced that their joint special meetings of shareholders on August 14, 2023 (“Special Meetings”) were adjourned until August 29, 2023 to provide additional time for the Funds to reach a quorum on the proposal, described in their definitive joint proxy statement dated July 10, 2023 as filed with the Securities and Exchange Commission (the “Proxy Statement”), to approve a new investment advisory agreement with abrdn, Inc. (the “Proposal”). The adjourned Special Meeting will recommence on August 29, 2023 at 9:00 a.m. EDT at the offices of the Funds, 100 Federal Street, Boston, MA. The record date for the adjourned Special Meetings remains the same, June 16, 2023.
Tekla Capital Management LLC Announces Proposed Transaction
Tekla Capital Management LLC (Tekla) announced today that it has entered into an agreement with abrdn Inc. for a strategic transaction involving four NYSE-listed healthcare & biotech thematic closed-end funds (the Funds), totaling $3.1 bn in assets under management.1
Tekla Healthcare Opportunities Fund Declares Monthly Cash Distribution
On August 10, 2022, Tekla Healthcare Opportunities Fund declared its monthly cash distribution of $0.1125 per share. The record date for the monthly cash distribution is August 22, 2022 and the payable date is August 31, 2022. The Fund will trade ex-distribution on August 19, 2022.
